1 – 20 of 20
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Melanoma Incidence and Mortality Trends in Sweden
2024) In JAMA Dermatology(
- Contribution to journal › Article
- 2022
-
Mark
Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)
(
- Contribution to journal › Article
- 2021
-
Mark
Multiple primary melanoma incidence trends over five decades, a nation-wide population-based study
(
- Contribution to journal › Article
-
Mark
CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015-2020 : implications for novel national recommendations
(
- Contribution to journal › Article
-
Mark
Surgery of metastatic melanoma after systemic therapy–the SUMMIST trial : study protocol for a randomized controlled trial
(
- Contribution to journal › Letter
-
Mark
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
(
- Contribution to journal › Article
- 2020
-
Mark
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
(
- Contribution to journal › Article
-
Mark
TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma
(
- Contribution to journal › Article
- 2019
-
Mark
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study) : Protocol for a multicenter phase II open label study
(
- Contribution to journal › Article
- 2018
-
Mark
Phenocopies in melanoma-prone families with germ-line CDKN2A mutations
(
- Contribution to journal › Article
-
Mark
CM-Score : A validated scoring system to predict CDKN2A germline mutations in melanoma families from Northern Europe
(
- Contribution to journal › Article
- 2017
-
Mark
Ökad kunskap om familjärt melanom och de bakomliggande generna
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Ökad kunskap om familjärt melanom och de bakomliggande generna
(
- Contribution to journal › Article
-
Mark
Cancer risks and survival in patients with multiple primary melanomas : Association with family history of melanoma and germline CDKN2A mutation status
(
- Contribution to journal › Article
- 2016
-
Mark
Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases
(
- Contribution to journal › Article
-
Mark
Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations
(
- Contribution to journal › Article
- 2015
-
Mark
CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
(
- Contribution to journal › Article
- 2014
-
Mark
High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.
(
- Contribution to journal › Article
- 2003
-
Mark
TGF-{beta} signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro.
(
- Contribution to journal › Article
- 2000
-
Mark
Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene expression in progeny cells
(
- Contribution to journal › Article